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Background: Serotonin (5-HT3) receptor antagonists are commonly used to decrease nausea and vomiting for
surgery patients. We conducted a systematic review on the comparative efficacy of 5-HT3 receptor antagonists.
Methods: Searches were done in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to
identify studies comparing 5-HT3 receptor antagonists with each other, placebo, and/or combined with other
antiemetic agents for patients undergoing surgical procedures. Screening search results, data abstraction, and risk of
bias assessment were conducted by two reviewers independently. Random-effects pairwise meta-analysis and
network meta-analysis (NMA) were conducted. PROSPERO registry number: CRD42013003564.
Results: Overall, 450 studies and 80,410 patients were included after the screening of 7,608 citations and 1,014 full-text
articles. Significantly fewer patients experienced nausea with any drug relative to placebo, except for ondansetron plus
metoclopramide in a NMA including 195 RCTs and 24,230 patients. Significantly fewer patients experienced vomiting
with any drug relative to placebo except for palonosetron plus dexamethasone in NMA including 238 RCTs and 12,781
patients. All agents resulted in significantly fewer patients with postoperative nausea and vomiting versus placebo in a
NMA including 125 RCTs and 16,667 patients.
Conclusions: Granisetron plus dexamethasone was often the most effective antiemetic, with the number needed to
treat ranging from two to nine.
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Systematic reviewBackground
Postoperative nausea and/or vomiting can be defined as
nausea and/or vomiting within 24 h of surgery [1, 2].
Between 20 % and 65 % of patients undergoing surgery
experience postoperative nausea and/or vomiting [2, 3]* Correspondence: sharon.straus@utoronto.ca
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creativecommons.org/publicdomain/zero/1.0/and the anesthetic agents administered during the pro-
cedure have been identified as a contributing factor.
Nausea and vomiting are associated with decreased qual-
ity of life and patient satisfaction [4, 5]. Vomiting can
also cause complications such as aspiration pneumonia
[6] and a longer hospital stay [7].
Serotonin (5-HT3) receptor antagonists reduce nausea
and vomiting by inhibiting vagal nerves in the central
nervous system and intestinal mucosa [8]. These agents
are recommended by clinical practice guidelines for pa-
tients undergoing surgery and at risk for nausea and/or
vomiting [9, 10].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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systematic review and network meta-analysis to assess the
comparative efficacy of 5-HT3 receptor antagonists.
Methods
Protocol
A protocol based on the Preferred Reporting Items for
Systematic reviews and Meta-Analysis for Protocols
(PRISMA-P) guidelines was developed [11]. We revised
our protocol using feedback from the research team and
the research users, including Health Canada, a depart-
ment of the federal government, who posed the original
query. The final protocol was registered with PROSPERO
(CRD42013003564) and published in an open-access jour-
nal [12]. As described in our protocol [12], our initial ob-
jective was to include data for patients undergoing surgery
and chemotherapy in the overall analysis for both safety
and efficacy outcomes. However, due to the extensive
number of studies that met the inclusion criteria, we subdi-
vided the analysis and presentation of results in separate
papers for chemotherapy and surgery, as well efficacy and
safety outcomes [13]. This paper focuses on the efficacy of
5-HT3 receptor antagonist for patients undergoing surgery.
Our methods are described briefly below.
Eligibility criteria
We included studies involving patients of any age undergo-
ing any type of surgery and who were given a 5-HT3 recep-
tor antagonist for nausea and/or vomiting (Additional file 1:
Appendix 1). Randomized controlled trials (RCTs), quasi-
RCTs, non-RCTs, interrupted time series, controlled be-
fore–after studies, and observational (cohort) studies were
eligible for inclusion. We limited our systematic review to
trials published in English due to resource constraints, and
excluded studies that were identified as fraudulent or were
retracted [14]. The primary outcome was the number of pa-
tients who vomited, and secondary outcomes were the num-
ber of patients with nausea and the number of patients with
both postoperative nausea and vomiting (PONV).
Information sources
Information sources included electronic databases
(MEDLINE, EMBASE, and the Cochrane Central Register
of Controlled Trials from inception until January 11, 2013),
trial protocol registries, and conference proceedings.
Study selection and data collection
Two reviewers screened the literature search results and
potentially relevant full-text articles, independently. The
same process was followed for data abstraction and
methodological quality/risk of bias appraisal. We con-
tacted authors as necessary; for example, to obtain add-
itional information.Appraisal of methodological quality and risk of bias
We used the Cochrane Effective Practice and Organization
of Care (EPOC) risk-of-bias tool to assess risk of bias for
experimental and quasi-experimental studies [15], and the
Newcastle–Ottawa Scale (NOS) [16] for cohort studies.
Synthesis of included studies
A random-effects pairwise meta-analysis on the odds ratio
(OR) scale was performed to combine studies addressing
the same clinical outcome and treatment comparison. We
decided to apply a random-effects model, as we expected
methodological and clinical heterogeneity across the in-
cluded studies that compared the same pairs of interven-
tions. For studies with dichotomous outcomes where zero
events were reported in one treatment arm, we added 0.5
to all cells. Between-study heterogeneity (τ2) was exam-
ined using the restricted maximum likelihood (REML)
[17] method, and quantified using the I2 statistic [18]. The
R 3.1.2 [19] and metafor package [20] were employed to
conduct all pairwise meta-analyses.
For a connected network diagram, we conducted a ran-
dom effects network meta-analysis to make inferences on
the comparative efficacy of the 5-HT3 receptor antagonists
[21]. Treatment nodes were selected by the clinicians and
statisticians on the research team. If a study compared dif-
ferent doses of a particular intervention, we included only
the recommended dose in the analysis [9, 10, 22–30].
Prior to conducting a network meta-analysis, we evalu-
ated the transitivity assumption by examining the com-
parability of the distributions of potential treatment-
effect modifiers across comparisons [31]. These included
age (children versus adults), timing of administration (all
time points versus during surgery), and risk of bias (all
versus removing high risk of bias for randomization,
allocation concealment, and blinding of outcome assessor).
We evaluated transitivity in each network, by visually
comparing the mode of the categorical potential effect
modifiers across treatment comparisons [32]. We also
assessed statistical inconsistency between different
sources of evidence in the network using a global χ2 test
derived from the design-by-treatment interaction model
[21]. In the presence of statistically significant inconsist-
ency, we applied the loop-specific approach [33, 34] to
locally assess the network and identify the treatment
comparisons responsible for inconsistency. In the net-
work meta-analysis and design-by-treatment interaction
models, we assumed common within-network hetero-
geneity, whereas in loop-specific method we assumed
common within-loop heterogeneity. We assumed com-
mon heterogeneity across treatment comparisons since
the included treatments are of the same nature and it
was clinically reasonable to share a common heterogeneity
parameter. In all approaches, we estimated the magnitude
of between-study heterogeneity using the REML method
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have been explored using network meta-regression ana-
lyses adjusting for potential effect modifiers. For each out-
come, we carried out subgroup analyses using time of
administration of antiemetics (all time periods versus dur-
ing surgery) and age (all ages versus children), and sensi-
tivity analyses excluding studies with high risk of
incomplete outcome data bias. Although our primary ana-
lyses were restricted to RCTs only, as a secondary analysis,
we included quasi-RCTs and non-RCTs to examine the
robustness of the network meta-analysis results.
We present the network meta-analysis summary of
treatment effects along with their 95 % confidence interval
(CI) and 95 % predictive interval (PrI). The PrI captures
both the uncertainty around the summary treatment effect
and between-study variance, and shows the interval within
which the treatment effect is expected to lie when a future
study is conducted [35, 36]. To visually assess the presenceFig. 1 Study flow. Details the flow of information through the different ph
included and excluded, and the reasons for their exclusionof reporting bias (including publication bias and small-
study effects), we used the comparison-adjusted funnel plot
[32]. We also ranked the effectiveness of the 5-HT3 agonist
receptors using the surface under the cumulative ranking
(SUCRA) curve [37]. Network meta-analyses were con-
ducted in Stata 13.0 [38] using the mvmeta command [39].
Results
Literature search
The literature search yielded 7,608 citations in total that
met the search criteria, of which 450 full text articles met
eligibility criteria for inclusion (444 primary publications
and six companion reports reporting on nine studies, Fig. 1;
Additional file 1: Appendix 2). Five unpublished confer-
ence abstracts were included in the review [40–44]. We
excluded 77 studies because we suspected or confirmed
that their results were fraudulent [14] and 535 studies
from previous reviews that did not fulfill our eligibilityases of the review, mapping out the number of records identified,
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file 1: Appendix 3).
Study and patient characteristics
The majority of the included studies had an RCT design
(97 %) with a short duration of follow-up of 12 to 24 h
(72 %). Most studies were published between 1995 and
2013 (94 %), and were mainly conducted in Asia (39 %),
North America (27 %), or Europe (24 %) (Table 1,
Additional file 1: Appendix 4).
The 5-HT3 receptor antagonists we examined were
ondansetron (0.1 − 48 mg/day; 76 %), granisetron (0.1 −
3 mg/day; 13 %), tropisetron (0.1 − 5 mg/day; 8 %),
dolasetron (12.5 − 200 mg/day; 7 %), palonosetron (0.025 −
0.25 mg/day; 3 %), and ramosetron (0.1− 0.6 mg/day; 2 %)
(Table 1, Additional file 1: Appendix 5). We also included
studies comparing combinations of 5-HT3 drugs adminis-
tered concomitantly with other antiemetics, e.g., dexa-
methasone (2–20 mg/day; 16 %), butyrophenone (3 %),
and benzamide (1 %).
Overall, 286 studies with dichotomous outcome data
were included in our analyses. Studies with continuous
outcome data and studies investigating the same 5-HT3
treatment in different doses were not included in the
analysis.
The median study size was 118 (interquartile range,
75–180) patients, whereas most patients were women
(72 %), and adults (59 %), with an American Society of
Anesthesiologists (ASA) physical status [45] of I or II
(60 %) undergoing obstetrical and gynecological (30 %)
surgery (Table 2, Additional file 1: Appendix 6). The in-
cluded studies often did not report patients’ history of
PONV (56 %). Similarly, a history of motion sickness
was reported in only 33 % of the studies; comorbidities
were rarely reported (5 %).
Methodological quality and risk of bias
Most of the included RCTs and quasi-RCTs had an
unclear or high risk of bias on the following items: allo-
cation concealment (59 %), baseline outcome character-
istics (89 %), incomplete outcome data (60 %), and
selective outcome reporting bias (97 %). When assessing
potential for funding bias, we considered a study at a
high or unclear risk of bias when it was funded by a
private industry or when an author on the publication
was employed by the company sponsoring the study,
which occurred in 92 % of the RCTs and quasi-RCTs
(Additional file 1: Appendices 7 and 8). Of the nine ob-
servational studies included in the analysis, eight used a
somewhat representative sample, two did not describe
ascertainment of exposure, all failed to demonstrate that
the outcome was not present at the start of the study,
six did not control for confounders, three did not de-
scribe the assessment of outcome, and all neglected toreport follow-up (Additional file 1: Appendix 9). The vis-
ual inspection of the comparison adjusted funnel plots
showed that there is no evidence for small-study effects
and publication bias (Additional file 1: Appendix 10).
Vomiting
The network meta-analysis for vomiting included 238
RCTs with a total of 12,781 patients. The network geom-
etry and included drugs can be found in Fig. 2a, whereas
the statistically significant results are available in Table 3
and the overall results in Additional file 1: Appendix 11.
The following treatment comparisons were statistically
significant using both the CIs and PrIs: all agents (except
for palonosetron plus dexamethasone and granisetron
plus droperidol intravenous (IV)) versus placebo, ondan-
setron plus droperidol IV versus ondansetron, granisetron
plus dexamethasone versus ondansetron, ondansetron
plus dexamethasone versus dolasetron, ondansetron plus
droperidol IV versus dolasetron, granisetron plus dexa-
methasone versus dolasetron, palonosetron plus dexa-
methasone versus ondansetron plus dexamethasone,
palonosetron plus dexamethasone versus ondansetron
plus droperidol IV, and palonosetron plus dexamethasone
versus granisetron plus dexamethasone (Fig. 3). According
to the SUCRA (Additional file 1: Appendix 12), the most
effective agents for vomiting were ondansetron plus
droperidol IV (85 % probability) and granisetron plus
dexamethasone (84 % probability). The within-network
heterogeneity in the network meta-analysis model was es-
timated at 0.15, and the evaluation of the network incon-
sistency using the design-by-treatment interaction model
suggested that there was no evidence of statistical incon-
sistency (χ2 = 49.27, degrees of freedom = 44, P = 0.271,
heterogeneity variance = 0.15).
In order to account for the treatment effect modifier
‘age’ (Additional file 1: Appendix 13), a subgroup ana-
lysis was conducted for 46 RCTs involving a total of
1,830 children (Table 3, Additional file 1: Appendix 11).
The following treatment comparisons were statistically
significant for vomiting: ondansetron versus placebo,
granisetron versus placebo, dolasetron versus placebo,
tropisetron versus placebo, ondansetron plus dexa-
methasone versus placebo, ondansetron plus droperi-
dol lV versus placebo, ondansetron plus metoclopramide
IV versus placebo, granisetron plus dexamethasone ver-
sus placebo, ondansetron plus dexamethasone versus
ondansetron, ondansetron plus dexamethasone versus
dolasetron, ondansetron plus dexamethasone versus
granisetron, and granisetron plus dexamethasone versus
dolasetron (Additional file 1: Appendix 11). According
to the SUCRA, the most effective agents for vomiting
in children were ondansetron plus dexamethasone
(83 % probability) and granisetron plus dexamethasone
(82 % probability).
Table 1 Study characteristics

















South America 9 2.03
Not reported 2 0.45
Study design
Randomized clinical trial 429 96.62
Cohort study 9 2.03
Non-randomized clinical trial 5 1.13





Not reported 380 85.59
Duration of follow-up **
0 to ≤6 13 2.93
>6 to ≤12 9 2.03
>12 to ≤24 319 71.85
>24 to ≤48 52 11.71
>48 to ≤72 14 3.15
>72 to ≤1 week 12 2.70
>1 week 3 0.68
Not reported 22 4.95
Interventions examined: frequency ***
Serotonin antagonists Reported as administered alone
(administered with dexamethasone)
Ondansetron 336 (46) 75.68 (10.36)
Granisetron 57 (15) 12.84 (3.38)
Tropisetron 35 (2) 7.88 (0.45)
Dolasetron 33 (3) 7.43 (0.68)
Palonosetron 14 (3) 3.15 (0.68)
Ramosetron 10 (1) 2.25 (0.23)









Serotonin antagonists given with other antiemetic
Serotonin antagonist + dexamethasone 70 15.77
Serotonin antagonist + butyrophenone 15 3.38
Serotonin antagonist + benzamide 5 1.13
Serotonin antagonist + antihistamine 3 0.68
Serotonin antagonist + NK-1 2 0.45
Serotonin antagonist + phenothiazine 2 0.45
Placebo or no treatment
293 65.99





Not reported 270 60.81
Hospital 113 25.45
Multi-center 31 6.98
Medical center 30 6.76
* Includes unpublished data; ** Duration is in hours unless otherwise noted;
*** Multiple interventions and comparators examined across the studies;
**** Multiple interventions and outcomes reported per study
NK-1 neurokinin 1 receptor antagonist, PONV postoperative nausea and vomiting
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‘timing of administration’ (Additional file 1: Appendix 14),
a subgroup analysis was conducted for 220 RCTs involving
10,811 patients when the agents were administered during
surgery (Additional file 1: Appendix 15). The results were
the same as for the primary analysis, except that ondanse-
tron plus droperidol IV was statistically superior to
granisetron, and ondansetron plus droperidol IV and gran-
isetron plus dexamethasone were superior to ramosetron.
According to the SUCRA for this subgroup analysis, the
most effective agents for vomiting were ondansetron plus
droperidol IV (88 % probability) and granisetron plus
dexamethasone (84 % probability).
In order to account for the treatment effect modifier
‘risk of bias’, a sensitivity analysis was conducted in which
11 RCTs were removed because of high risk of incomplete
outcome data bias (Additional file 1: Appendix 15); the
same results were observed, except granisetron plus
Table 2 Patient characteristics
Total no. of patients 80,410
Mean, Median sample size 181, 118
Mean % female 72
No. of studies




Children only (aged <18 yr) 75 16.89
Adults only (aged ≥18 yr to ≤65 yr) 262 59.01
Children and adults (aged ≤65 yr) 17 3.83
Adults and elderly (aged ≥18 yr) 76 17.12
All ages 9 2.03
Not reported 5 1.13
American Society of Anesthesiologists
(ASA) physical status
I 15 3.38
I or II 266 59.91
I or II or III 87 19.59
II or III 4 0.90
Not reported 72 16.22
Surgery type
Obstetric and gynecological 134 30.18
Gastrointestinal 51 11.49
Eye 35 7.88










Miscellaneous (includes multiple surgery
types, abdominal surgery, and plastic
surgery unspecified)
103 23.20
Not reported 4 0.90
History of motion sickness
Yes 147 33.11
No or not reported 297 66.89
History of postoperative nausea
and vomiting
Yes 197 44.37
No or not reported 247 55.63
Comorbidities **
Not reported 415 93.47
Diabetes mellitus 9 2.03
Cardiovascular 8 1.80





Liver disease 2 0.45
Asthma 1 0.23
Disorder of the ear 1 0.23
Mental health 1 0.23
Osteoarthritis 1 0.23
Urological 1 0.23
* Includes unpublished data; ** Some studies considered more than
one comorbidity
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vomiting compared with ramosetron (OR, 0.52;, 95 % CI,
0.27–0.99). In another sensitivity analysis, in which four
cohort studies [46–49], two non-randomized controlled
trials [50, 51], and one controlled before–after study [52]
were added to the included studies, all of the results were
the same, except that the differences between ondansetron
plus dexamethasone and granisetron or ramosetron and
between ondansetron plus metoclopramide IV and palo-
nosetron plus dexamethasone were no longer statistically
significant (Additional file 1: Appendix 15).
Nausea
The network meta-analysis for nausea included 195
RCTs with a total of 24,230 patients. The network geom-
etry and included drugs can be found in Fig. 2b. We
present the statistically significant treatment effect esti-
mates derived through the network meta-analysis model
in Table 3 and overall results in Additional file 1:
Appendix 11. Using both the CIs and PrIs, the only
treatment comparisons that were statistically significant
for nausea were granisetron versus placebo (OR, 0.35;
95 % PrI, 0.13–0.91), ondansetron plus dexamethasone
versus placebo (OR, 0.28; 95 % PrI, 0.10–0.76), palonose-
tron versus placebo (OR, 0.30; 95 % PrI, 0.10–0.89),
ramosetron versus placebo (OR, 0.32; 95 % PrI, 0.12–
0.86), ondansetron plus droperidol IV versus placebo
(OR, 0.26; 95 % PrI, 0.09–0.80), granisetron plus dexa-
methasone versus placebo (OR, 0.20; 95 % PrI, 0.07–
0.57), dolasetron plus droperidol IV versus placebo (OR,
0.19; 95 % PrI, 0.05–0.77), and granisetron plus droperi-
dol IV versus placebo (OR, 0.21; 95 % PrI, 0.05–0.87)
(Additional file 1: Appendices 11 and 16). According to
the SUCRA (Additional file 1: Appendix 17), the most
effective agents for nausea were granisetron plus dexa-
methasone (82 % probability) and dolasetron plus
droperidol IV (78 % probability). The within-network
heterogeneity in the network meta-analysis model was
Fig. 2 Network geometry. Network meta-analysis diagrams for vomiting, nausea, and PONV. Nodes are weighted according to the number of patients
included in the corresponding treatments, and edges are weighted according to the number of studies included in the respective comparisons
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model suggested that there was no statistically signifi-
cant inconsistency (χ2 = 26.65, degrees of freedom = 41,
P = 0.959, heterogeneity variance = 0.27).
In order to account for the treatment effect modifier
‘age’ (Additional file 1: Appendix 13), a subgroup
analysis was conducted for 11 RCTs involving 1,326 chil-
dren (Table 3, Additional file 1: Appendix 11). The
following treatment comparisons were statistically sig-
nificant for nausea: ondansetron versus placebo, dolase-
tron versus placebo, ondansetron plus dexamethasone
versus placebo, and granisetron plus dexamethasone ver-
sus placebo (Additional file 1: Appendix 11). According
to the SUCRA, the most effective agents for nausea in
children were granisetron plus dexamethasone (84 %
probability) and ondansetron plus droperidol IV (81 %
probability).
In order to account for the treatment effect modifier
‘timing of administration’ (Additional file 1: Appendix 14),
a subgroup analysis was conducted for 175 RCTs involving21,844 patients when the agents were administered during
surgery (Additional file 1: Appendix 18). All of the results
were the same as for the primary analysis, except that the
difference between tropisetron and ondansetron plus dexa-
methasone was no longer statistically significant. Accord-
ing to the SUCRA for this subgroup analysis, the most
effective agents for nausea were granisetron plus dexa-
methasone (82 % probability) and dolasetron plus droperi-
dol IV (77 % probability).
In order to account for the treatment effect modifier
‘risk of bias’, a sensitivity analysis was conducted in
which 10 RCTs were removed because of high risk of in-
complete outcome data bias [53–62], and the results
were unchanged from the primary analysis (Additional
file 1: Appendix 18). In another sensitivity analysis, in
which two cohort studies [46, 49] and two non-
randomized controlled trials [50, 51] were added to the
included studies, all of the results were the same, except
that the differences between palonosetron and dolase-
tron and between dolasetron plus dexamethasone and
Table 3 Statistically significant results of network meta-analysis for all time periods of drug administration
All ages Children only
Treatment comparison No. of
studies
MA estimate:
OR (95 % CI) *
NMA estimate:




OR (95 % CI) *
NMA estimate:
OR (95 % CI)
Vomiting 238 RCTs and 12,781 patients 46 RCTs and 1,830 patients
Ondansetron vs. placebo 146 0.35 (0.32–0.39) 0.36 (0.33–0.40) 34 0.30 (0.24–0.38) 0.30 (0.24–0.38)
Granisetron vs. placebo 27 0.24 (0.16–0.34) 0.26 (0.21–0.34) 4 0.21 (0.08–0.56) 0.23 (0.12–0.48)
Dolasetron vs. placebo 7 0.42 (0.21–0.83) 0.44 (0.30–0.63) 3 0.41 (0.23–0.75) 0.39 (0.19–0.78)
Tropisetron vs. placebo 15 0.32 (0.22–0.48) 0.32 (0.23–0.43) 3 0.18 (0.09–0.36) 0.18 (0.08–0.41)
Ondansetron + DEX vs. placebo 12 0.16 (0.09–0.27) 0.16 (0.12–0.23) 5 0.06 (0.03–0.17) 0.07 (0.03–0.15)
Palonosetron vs. placebo 4 0.53 (0.38–0.73) 0.38 (0.24–0.60) NA NA NA
Ramosetron vs. placebo 5 0.42 (0.26–0.68) 0.28 (0.18–0.43) NA NA NA
Ondansetron + DROP vs. placebo 2 0.15 (0.07–0.31) 0.14 (0.08–0.26) 1 0.13 (0.05–0.33) 0.11 (0.04–0.33)
Ondansetron +METO vs. placebo 2 0.16 (0.06–0.43) 0.15 (0.06–0.42) 2 0.16 (0.06–0.43) 0.18 (0.06–0.53)
Granisetron + DEX vs. placebo 5 0.16 (0.08–0.31) 0.15 (0.09–0.24) 2 0.08 (0.03–0.27) 0.09 (0.02–0.31)
Dolasetron + DEX vs. placebo 1 0.06 (0.01–0.30) 0.18 (0.06–0.49) NA NA NA
Dolasetron + DROP vs. placebo 1 0.16 (0.07–0.35) 0.19 (0.07–0.52) NA NA NA
Granisetron + DROP vs. placebo 2 0.30 (0.05–1.66) 0.31 (0.11–0.82) NA NA NA
Granisetron vs. ondansetron 12 0.52 (0.34–0.81) 0.73 (0.56–0.94) NA NA 0.78 (0.37–1.63)
Ondansetron + DEX vs. ondansetron 15 0.50 (0.33–0.75) 0.46 (0.33–0.63) 3 0.24 (0.12–0.47) 0.23 (0.11–0.49)
Ondansetron + DROP vs. ondansetron 5 0.43 (0.24–0.78) 0.39 (0.21–0.71) 1 0.31 (0.12–0.77) 0.37 (0.13–1.09)
Granisetron + DEX vs. ondansetron NA NA 0.41 (0.25–0.67) NA NA 0.28 (0.08–1.04)
Dolasetron vs. granisetron NA NA 1.66 (1.07–2.57) NA NA 1.65 (0.61–4.47)
Ondansetron + DEX vs. granisetron NA NA 0.63 (0.42–0.94) NA NA 0.30 (0.11–0.83)
Granisetron + DEX vs. granisetron 7 0.39 (0.20–0.77) 0.57 (0.35–0.92) 1 0.14 (0.02–1.23) 0.36 (0.09–1.50)
Ondansetron + DEX vs. dolasetron NA NA 0.38 (0.23–0.62) NA NA 0.18 (0.07–0.50)
Ondansetron + DROP vs. dolasetron NA NA 0.32 (0.16–0.65) NA NA 0.29 (0.08–1.04)
Granisetron + DEX vs. dolasetron NA NA 0.34 (0.19–0.63) NA NA 0.22 (0.05–0.95)
Ondansetron + DEX vs. tropisetron NA NA 0.52 (0.33–0.82) NA NA 0.40 (0.13–1.22)
Ondansetron + DROP vs. tropisetron NA NA 0.45 (0.23–0.88) NA NA 0.64 (0.16–2.48)
Granisetron + DEX vs. tropisetron NA NA 0.47 (0.26–0.84) NA NA 0.48 (0.10–2.25)
Palonosetron vs. ondansetron + DEX NA NA 2.32 (1.33–4.07) NA NA NA
Ramosetron vs. ondansetron + DEX NA NA 1.71 (1.01–2.90) NA NA NA
Palonosetron +DEX vs. ondansetron +DEX NA NA 8.68 (1.19–63.20) NA NA NA
Ondansetron + DROP vs. palonosetron NA NA 0.37 (0.17–0.78) NA NA NA
Granisetron + DEX vs. palonosetron NA NA 0.39 (0.20–0.75) NA NA NA
Palonosetron +DEX vs. ondansetron +DROP NA NA 10.13 (1.31–78.58) NA NA NA
Palonosetron +DEX vs. ondansetron +METO NA NA 9.38 (1.03–85.06) NA NA NA
Palonosetron +DEX vs. granisetron +DEX NA NA 9.60 (1.28–72.03) NA NA NA
Nausea 195 RCTs and 24,230 patients 11 RCTs and 1,326 patients
Ondansetron vs. placebo 121 0.46 (0.40–0.52) 0.46 (0.41–0.52) 10 0.44 (0.29–0.68) 0.45 (0.30–0.66)
Granisetron vs. placebo 21 0.35 (0.23–0.52) 0.35 (0.26–0.47) NA NA NA
Dolasetron vs. placebo 9 0.59 (0.48–0.73) 0.60 (0.43–0.86) 1 0.29 (0.11–0.73) 0.26 (0.09–0.74)
Tropisetron vs. placebo 15 0.51 (0.40–0.66) 0.48 (0.35–0.65) NA NA NA
Ondansetron + DEX vs. placebo 8 0.21 (0.14–0.34) 0.28 (0.19–0.41) 2 0.21 (0.08–0.57) 0.22 (0.08–0.61)
Palonosetron vs. placebo 3 0.48 (0.33–0.68) 0.30 (0.17–0.53) NA NA NA
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Table 3 Statistically significant results of network meta-analysis for all time periods of drug administration (Continued)
Ramosetron vs. placebo 5 0.35 (0.18–0.68) 0.32 (0.22–0.47) NA NA NA
Ondansetron + DROP vs. placebo 2 0.31 (0.06–1.55) 0.26 (0.14–0.49) 1 0.07 (0.00–1.26) 0.07 (0.00–1.38)
Granisetron + DEX vs. placebo 4 0.21 (0.11–0.39) 0.20 (0.12–0.34) 1 0.09 (0.02–0.49) 0.10 (0.02–0.53)
Dolasetron + DEX vs. placebo 1 0.28 (0.05–1.53) 0.21 (0.07–0.61) NA NA NA
Dolasetron + DROP vs. placebo 1 0.17 (0.08–0.36) 0.19 (0.07–0.54) NA NA NA
Granisetron + DROP vs. placebo 2 0.22 (0.08–0.61) 0.21 (0.07–0.62) NA NA NA
Ondansetron + DEX vs. ondansetron 14 0.68 (0.48–0.96) 0.61 (0.42–0.89) 1 0.53 (0.11–2.60) 0.48 (0.16–1.43)
Granisetron + DEX vs. ondansetron NA NA 0.43 (0.25–0.73) NA NA 0.21 (0.04–1.23)
Dolasetron vs. granisetron NA NA 1.73 (1.10–2.72) NA NA NA
Granisetron + DEX vs. granisetron 6 0.59 (0.39–0.88) 0.56 (0.33–0.95) NA NA NA
Ondansetron + DEX vs. dolasetron NA NA 0.47 (0.28–0.78) NA NA 0.81 (0.19–3.50)
Palonosetron vs. dolasetron NA NA 0.50 (0.26–0.97) NA NA NA
Ramosetron vs. dolasetron NA NA 0.53 (0.31–0.88) NA NA NA
Ondansetron + DROP vs. dolasetron NA NA 0.44 (0.21–0.89) NA NA 0.28 (0.01–6.17)
Granisetron + DEX vs. dolasetron NA NA 0.33 (0.17–0.62) NA NA 0.36 (0.05–2.66)
Dolasetron + DEX vs. dolasetron 2 0.33 (0.15–0.72) 0.35 (0.13–0.97) NA NA NA
Dolasetron + DROP vs. dolasetron 1 0.35 (0.17–0.73) 0.32 (0.11–0.89) NA NA NA
Ondansetron + DEX vs. tropisetron NA NA 0.59 (0.36–0.95) NA NA NA
Granisetron + DEX vs. tropisetron NA NA 0.41 (0.22–0.76) NA NA NA
Postoperative nausea and vomiting 125 RCTs and 16,667 patients 14 RCTs and 2,394 patients
Ondansetron vs. placebo 89 0.30 (0.26–0.35) 0.31 (0.27–0.36) 11 0.33 (0.18–0.60) 0.34 (0.19–0.62)
Granisetron vs. placebo 16 0.23 (0.14–0.37) 0.23 (0.16–0.32) 2 0.54 (0.26–1.12) 0.32 (0.08–1.23)
Dolasetron vs. placebo 5 0.27 (0.14–0.52) 0.25 (0.14–0.43) NA NA NA
Tropisetron vs. placebo 8 0.39 (0.28–0.53) 0.36 (0.24–0.54) NA NA NA
Ondansetron + DEX vs. placebo 8 0.12 (0.07–0.20) 0.15 (0.10–0.22) 1 0.20 (0.06–0.66) 0.27 (0.04–1.61)
Palonosetron vs. placebo NA NA 0.11 (0.03–0.40) NA NA NA
Ramosetron vs. placebo 4 0.30 (0.15–0.59) 0.26 (0.16–0.41) NA NA NA
Ondansetron + DROP vs. placebo 2 0.13 (0.05–0.34) 0.11 (0.05–0.24) 1 0.12 (0.04–0.34) 0.12 (0.02–0.71)
Granisetron + DEX vs. placebo 4 0.06 (0.02–0.17) 0.09 (0.05–0.16) NA NA NA
Palonosetron + DEX vs. placebo NA NA 0.12 (0.02–0.64) NA NA NA
Dolasetron + DROP vs. placebo 1 0.17 (0.08–0.36) 0.12 (0.04–0.35) NA NA NA
Granisetron + DROP vs. placebo 2 0.17 (0.07–0.38) 0.16 (0.06–0.40) NA NA NA
Ondansetron + DEX vs. ondansetron 11 0.48 (0.33–0.72) 0.46 (0.31–0.69) 1 1.00 (0.36–2.75) 0.78 (0.13–4.65)
Ondansetron + DROP vs. ondansetron 3 0.39 (0.20–0.75) 0.35 (0.16–0.77) NA NA NA
Granisetron + DEX vs. ondansetron 1 0.22 (0.04–1.21) 0.30 (0.17–0.53) NA NA NA
Granisetron + DEX vs. granisetron 8 0.48 (0.29–0.77) 0.41 (0.24–0.69) NA NA NA
Granisetron + DEX vs. dolasetron NA NA 0.37 (0.17–0.82) NA NA NA
Ondansetron + DEX vs. tropisetron NA NA 0.41 (0.23–0.73) NA NA NA
Ondansetron + DROP vs. tropisetron NA NA 0.31 (0.13–0.75) NA NA NA
Granisetron + DEX vs. tropisetron NA NA 0.26 (0.13–0.52) NA NA NA
Granisetron + DEX vs. ramosetron NA NA 0.36 (0.18–0.75) NA NA NA
* Meta-analysis was not conducted for treatment comparisons where only 1 trial was included. In that situation, the direct estimate was obtained from the single trial
CI confidence interval, DEX dexamethasone, DROP droperidol (intravenous), MA meta-analysis, METO metoclopramide (intravenous), NA not applicable, NMA network
meta-analysis, OR odds ratio
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Fig. 3 Network meta-analysis results for vomiting. All treatments are compared to placebo. The black horizontal lines represent the 95 % confidence
intervals (CI) of the summary treatment effects and red horizontal lines the 95 % predictive intervals (PrI). Results are presented on the odds ratio scale
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(Additional file 1: Appendix 18).
Postoperative nausea and vomiting
The network meta-analysis for PONV included 125
RCTs with 16,667 patients. The network geometry and
included drugs can be found in Fig. 2c, statistically sig-
nificant results are presented in Table 3, and the overall
results in Additional file 1: Appendix 11. According to
both the CIs and PrIs, the following treatment compari-
sons were statistically significant for PONV: all agents
versus placebo except for tropisetron, granisetron plus
dexamethasone versus ondansetron, and granisetron
plus dexamethasone versus tropisetron (Additional
file 1: Appendix 19). According to the SUCRA, the
most effective agents for PONV were granisetron plus
dexamethasone (86 % probability) and ondansetron
plus droperidol IV (78 % probability; Additional file 1:
Appendices 11 and 20). The within-network heterogen-
eity in the network meta-analysis model was estimated
at 0.25, and the design-by-treatment interaction model
suggested that there was no statistically significant in-
consistency (χ2 = 26.58, degrees of freedom= 32, P = 0.737,
heterogeneity variance = 0.26).
In order to account for the treatment effect modifier
‘age’ (Additional file 1: Appendix 13), a subgroup ana-
lysis was conducted for 14 RCTs involving a total of
2,394 children (Table 3, Additional file 1: Appendix 11).
The following treatment comparisons were statistically
significant: ondansetron versus placebo and ondansetronplus droperidol IV versus placebo. According to the
SUCRA, the most effective agents for PONV in children
were ondansetron plus droperidol IV (85 % probability)
and ondansetron plus dexamethasone (59 % probability).
In order to account for the treatment effect modifier
‘timing of administration’ (Additional file 1: Appendix 14),
a subgroup analysis was conducted for 116 RCTs involving
12,415 patients in which the agents were administered dur-
ing surgery (Additional file 1: Appendix 21). All of the re-
sults were the same as for the primary analysis, except that
ondansetron plus dexamethasone was statistically superior
to ramosetron. According to the SUCRA for this subgroup
analysis, the most effective agents for PONV were granise-
tron plus dexamethasone (84 % probability) and ondanse-
tron plus droperidol IV (79 % probability).
In order to account for the treatment effect modifier
‘risk of bias’, a sensitivity analysis was conducted in which
10 RCTs were removed because of high risk of incom-
plete outcome data bias (Additional file 1: Appendix 21)
[53–55, 58, 59, 61–65]; the results were unchanged from
the primary analysis, except that the risk of PONV was sig-
nificantly higher with tropisetron than with granisetron. In
another sensitivity analysis, two cohort studies [46, 49] and
three non-randomized controlled trials [50, 51, 66] were
added to the included studies, and the same results were
observed (Additional file 1: Appendix 11).
Discussion
Administration of most 5-HT3 antagonists led to signifi-
cantly fewer patients experiencing nausea, vomiting, and
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sponding PrIs were not statistically significant, suggest-
ing that the statistically significant treatment effects
might change should a new study become available. For
all age groups and across all outcomes, the most effect-
ive agents were granisetron plus dexamethasone. For
adults, the most effective agents were ondansetron plus
droperidol IV; and for children, the most effective agents
were ondansetron plus dexamethasone.
We also conducted a systematic review and network
meta-analysis on the safety of these medications [13].
Our network meta-analysis results suggested that
granisetron plus dexamethasone increases the risk of
arrhythmia. However, a statistically significant increase in
the risk of delirium was not observed in another network
meta-analysis. In a meta-analysis including three studies
for ondansetron versus placebo, no statistically significant
results were observed for mortality. Only two studies re-
ported prolongation of the QT interval; meta-analysis
was not feasible because the studies compared different
interventions.
Our network meta-analysis results for vomiting and
PONV are similar to those of a previous network meta-
analysis that examined only these two outcomes [67].
The only difference was that, unlike the current study,
the earlier analysis showed that granisetron was signifi-
cantly better than ondansetron and dolasetron for
PONV. However, we included 378 studies involving a
total of 68,167 patients that were not included in the
earlier review. Although we are aware of other system-
atic reviews and meta-analyses of 5-HT3 receptor antag-
onists [14, 68], the previous researchers did not conduct
a network meta-analysis, and therefore the results can-
not be compared. Notably, because of our comprehen-
sive literature search and broad eligibility criteria, we
included 205 studies involving a total of 43,075 patients
that were not included in those previous reviews
(Additional file 1: Appendix 22).
The included studies were limited by having an un-
clear or high risk of bias on important components,
including allocation concealment, selective outcome
reporting bias, and potential for funding bias. Further,
this systematic review process had some inherent limita-
tions. Slight changes to the original protocol [12] were
necessary, such as preparing a separate paper for pa-
tients undergoing chemotherapy, as well as one focused
on the safety of these agents for patients with surgery
[13]. Furthermore, it was assumed that the effects of the
different doses and durations were identical across the
treatments, and that they defined the same node they
belong to. We are currently exploring these assumptions
in another paper [69]. Although study designs above and
beyond RCTs were included, the network meta-analysis
was limited to the RCTs in order to increase theconfidence of the results. We also were unable to
present the results from the hundreds of meta-analyses
conducted, as well as the raw data; these are available
from the corresponding author upon request. Although
the analyses were adjusted to account for the treatment
effect modifiers (age, timing of administration, and risk
of bias), the results might be influenced by effect modi-
fiers that we were unaware of. However, the statistical
evaluation of the transitivity assumption using the
design-by-treatment interaction model suggested there
was no evidence of inconsistency. Finally, 77 studies
were excluded because they contained data known to be
fraudulent or were retracted [14].
Conclusions
In conclusion, granisetron plus dexamethasone was often
the most effective antiemetic across the effectiveness out-
comes considered here, with the number needed to treat
ranging from two to nine. A study that examines the ad-
ministration of these agents at different dosages would
provide further clarity to this important issue and our
team is currently working on such an initiative [70].
Additional file
Additional file 1: Appendices 1–22.
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